Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 6/20 | 0.50 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.50 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.50 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | PAK4 | O96013 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | PLK1 | P53350 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | CCNC | P24863 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13125847 | 0.87 | CSNK2A2 (0.55) | HSP90AB1CSNK2A2CSNK2BCSNK2A1KDR | |
| SCHEMBL1424692 | 0.85 | HSP90AB1 (0.47) | HSP90AB1ALDH1A1HPGDKDM4EMAPT | |
| SCHEMBL27663682 | 0.84 | HSP90AB1 (0.55) | HSP90AB1ALDH1A1KDM4EMAPTCCNC | |
| SCHEMBL18750388 | 0.83 | HSP90AB1 (0.54) | HSP90AB1CSNK2A2CSNK2BCSNK2A1KDR | |
| SCHEMBL1753901 | 0.82 | CSNK2A2 (0.47) | CSNK2A2CSNK2BCSNK2A1KDRPAK4 | |
| SCHEMBL14611037 | 0.81 | CSNK2A2 (0.46) | HSP90AB1CSNK2A2CSNK2BCSNK2A1KDR | |
| SCHEMBL1753899 | 0.81 | CSNK2A2 (0.49) | CSNK2A2CSNK2BCSNK2A1KDRPAK4 | |
| SCHEMBL1937266 | 0.78 | ABL1 (0.52) | CSNK2A2CSNK2BCSNK2A1KDRPAK4 | |
| SCHEMBL13109542 | 0.77 | CSNK2A1 (0.58) | HSP90AB1CSNK2A2CSNK2BCSNK2A1KDR | |
| SCHEMBL5254463 | 0.76 | ABL1 (0.53) | HSP90AB1CSNK2A2CSNK2BCSNK2A1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675861-B1 | PYRIMIDOTHIOPHENE COMPOUNDS | VERNALIS R&D LTD (GB) | 2015-12-23 | — | — | EP | disclosed |
| EP-1675861-B1 | PYRIMIDOTHIOPHENE COMPOUNDS | VERNALIS R&D LTD (GB) | 2015-12-23 | — | — | EP | disclosed |
| US-8642594-B2 | Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors | VERNALIS (R&D) LIMITED (GB) | 2014-02-04 | — | — | US | disclosed |
| US-8642594-B2 | Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors | VERNALIS (R&D) LIMITED (GB) | 2014-02-04 | — | — | US | disclosed |
| US-8642594-B2 | Substituted thieno[2,3-d]pyrimidines as HSP90 inhibitors | VERNALIS (R&D) LIMITED (GB) | 2014-02-04 | — | — | US | disclosed |
| US-20120053345-A1 | Indazole Compounds | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053345-A1 | Indazole Compounds | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053345-A1 | Indazole Compounds | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | US | disclosed |
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| WO-2007117465-A2 | INDAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007117465-A2 | INDAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-10-18 | — | — | WO | disclosed |
| US-20070244133-A1 | Thienopyrimidines and Thiazolopyrimidines for Use in Medicine | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244133-A1 | Thienopyrimidines and Thiazolopyrimidines for Use in Medicine | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
| EP-1755610-A2 | THIENOPYRIMIDINES AND THIAZOLOPYRIMIDINES FOR USE IN MEDICINE | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | disclosed |
| US-20070043044-A1 | Pyrimidothiophene compounds | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| US-20070043044-A1 | Pyrimidothiophene compounds | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| EP-1675861-A1 | PYRIMIDOTHIOPHENE COMPOUNDS | Vernalis (Cambridge) Limited (GB) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005117890-A2 | THIENOPYRIMIDINES AND THIAZOLOPYRIMIDINES FOR USE IN MEDICINE | ASTRAZENECA AB (SE) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005021552-A1 | PYRIMIDOTHIOPHENE COMPOUNDS | VERNALIS (CAMBRIDGE) LTD (GB) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043044-A1 | Pyrimidothiophene compounds | ALK, HSP90AA1, HSP90AB1 | HSP90AB1 3/4885CSNK2A2 891/4885CSNK2B 1421/4885 |
| US-20070244133-A1 | Thienopyrimidines and Thiazolopyrimidines for Use in Medicine | CXCR4, CXCR1, CXCR3 | HSP90AB1 3621/4885CSNK2A2 2087/4885CSNK2B 2576/4885 |
| US-20120053345-A1 | Indazole Compounds | CYP3A43, CYP3A7, UGT1A1 | HSP90AB1 1599/4885CSNK2A2 1148/4885CSNK2B 945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.